|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Desirudin#Drug Interactions]] |
| {{Desirudin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| Any agent which may enhance the risk of hemorrhage should be discontinued prior to initiation of desirudin therapy. These agents include medications such as Dextran 40, systemic [[glucocorticoids]], [[thrombolytics]], and [[anticoagulants]]. If co-administration cannot be avoided, close clinical and laboratory monitoring should be conducted. During prophylaxis of [[venous thromboembolism]], concomitant treatment with heparins (unfractionated and low-molecular weight heparins) or dextrans is not recommended. The effects of desirudin and unfractionated heparins on prolongation of aPTT are additive.
| |
| | |
| As with other anticoagulants, desirudin should be used with caution in conjunction with drugs which affect platelet function. These medications include systemic salicylates, [[NSAIDS]] including [[ketorolac]], [[acetylsalicylic acid]], [[ticlopidine]], [[dipyridamole]], [[sulfinpyrazone]], [[clopidogrel]], [[abciximab]] and other [[glycoprotein]] IIb/IIIa antagonists (seePRECAUTIONS, Laboratory Tests).
| |
| | |
| Use in patients switching from oral anticoagulants to Iprivask or from Iprivask to oral anticoagulants. The concomitant administration of warfarin did not significantly affect the pharmacokinetic effects of desirudin. When warfarin and desirudin were co-administered, greater inhibition of hemostasis measured by activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) was observed. If a patient is switched from oral anticoagulants to Iprivask therapy or from Iprivask to oral anticoagulants, the anticoagulant activity should continue to be closely monitored with appropriate methods. That activity should be taken into account in the evaluation of the overall coagulation status of the patient during the switch.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = IPRIVASK (DESIRUDIN) KIT [MARATHON PHARMACEUTICALS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d768eca6-b25d-4aec-905f-b6a89e89ff29 | publisher = | date = | accessdate = 3 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Direct thrombin (II) inhibitors]]
| |
| [[Category:Anticoagulants]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |